Skip to main content

Advertisement

SpringerLink
Log in

A Pitfall of the Androgen Deprivation Therapy for Salivary Duct Carcinoma: Hormonal Therapy-Induced Castrate-Resistant Prostate Cancer

  • Case Report
  • Published:
Journal of Maxillofacial and Oral Surgery Aims and scope Submit manuscript

Abstract

Introduction

Salivary duct carcinoma (SDC) is a rare, high-grade salivary gland malignancy. Recently, targeting the androgen receptor (AR) is one of the most promising new therapeutic strategies for AR-positive SDC.

Case Review

In this report, a 70-year-old man who was diagnosed with an AR-positive SDC underwent androgen deprivation therapy (ADT) as a treatment for recurrence after primary therapy. The ADT well contributed to control of SDC; however, the patient was referred to urologists for urinary hesitancy and slow flow and he was diagnosed as having castration-resistant prostate cancer.

Literature Review

Since SDC is a rare disease, it has been difficult to establish the most effective therapy. Nevertheless, several papers have reported the clinical benefit of ADT for AR-positive SDC, and the latest version of the National Comprehensive Cancer Network guidelines also states the importance of assessing for the presence of AR in SDC.

On the other hand, in the field of urology, it is also known that although ADT is initially effective in prostate cancer patients, prostate cancer often develops into castrate-resistant prostate cancer due to the adaptation of prostate cancer cells to ADT for survival and growth.

Conclusion

We reported a case of castrate-resistant prostate cancer diagnosed during the ADT for metastatic SDC. The present case emphasizes the importance of screening for prostate cancer at the initiation of ADT treatment and during treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

The data that support the findings of this study are available from the corresponding author, Shugo Yajima, upon reasonable request.

Abbreviations

ADT:

Androgen deprivation therapy

AR:

Androgen receptors

CAB:

Combined androgen blockade

CRPC:

Castration-resistant prostate cancer

CT:

Computed tomography

DWI:

Diffusion-weighted magnetic resonance image

HER2:

Human epidermal growth factor receptor 2

LH:

Luteinizing hormone

MR:

Magnetic resonance

MRI:

Magnetic resonance imaging

NSE:

Neuron-specific enolase

PET:

Positron emission tomography

PD:

Progressive disease

PSA:

Prostate-specific antigen

SD:

Stable disease

SDC:

Salivary duct carcinoma

References

  1. Guzzo M, Di Palma S, Grandi C, Molinari R (1997) Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 19(2):126–133. https://doi.org/10.1002/(sici)1097-0347(199703)19:2%3c126::aid-hed7%3e3.0.co;2-6

    Article  CAS  Google Scholar 

  2. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M (2001) Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 93(5):344–350. https://doi.org/10.1002/cncr.9050

    Article  CAS  Google Scholar 

  3. Kleinsasser O, Klein HJ, Hübner G (1968) Salivary duct carcinoma: a group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 192(1):100–105

    Article  CAS  Google Scholar 

  4. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74(2):134–148. https://doi.org/10.1016/j.critrevonc.2009.10.004

    Article  Google Scholar 

  5. Fan CY, Wang J, Barnes EL (2000) Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 24(4):579–586. https://doi.org/10.1097/00000478-200004000-00014

    Article  CAS  Google Scholar 

  6. van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E et al (2019) Adjuvant androgen deprivation therapy for poor-risk androgen receptor–positive salivary duct carcinoma. Eur J Cancer 110:62–70. https://doi.org/10.1016/j.ejca.2018.12.035

    Article  CAS  Google Scholar 

  7. Jaspers HCJ, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WTA et al (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29(16):e473–e476. https://doi.org/10.1200/JCO.2010.32.8351

    Article  Google Scholar 

  8. Nakaguro M, Tada Y, Faquin WC, Sadow PM, Wirth LJ, Nagao T (2020) Salivary duct carcinoma: updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathol 128(10):693–703. https://doi.org/10.1002/cncy.22288

    Article  CAS  Google Scholar 

  9. Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6(2):76–85. https://doi.org/10.1038/ncpuro1296

    Article  CAS  Google Scholar 

  10. Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M et al (2017) Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget 8(12):49–67. https://doi.org/10.18632/oncotarget.14850

    Article  Google Scholar 

Download references

Funding

Not applicable

Author information

Authors and Affiliations

  1. National Cancer Center Hospital East, 6-5-1 Kashiwa no ha, Kashiwa city, Chiba, 277–8577, Japan

    Shugo Yajima, Yasukazu Nakanishi, Shunya Matsumoto, Kenji Tanabe & Hitoshi Masuda

Authors
  1. Shugo Yajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasukazu Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shunya Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenji Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hitoshi Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SY wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Corresponding author

Correspondence to Shugo Yajima.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

Ethical approval to report this case was obtained from National Cancer Center Institutional Review Board.

Consent for Publication

Informed consent document clearly spells this out at the time of participation.

Consent to Participate

Informed consent document clearly spells this out at the time of participation.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yajima, S., Nakanishi, Y., Matsumoto, S. et al. A Pitfall of the Androgen Deprivation Therapy for Salivary Duct Carcinoma: Hormonal Therapy-Induced Castrate-Resistant Prostate Cancer. J. Maxillofac. Oral Surg. 21, 1097–1100 (2022). https://doi.org/10.1007/s12663-022-01730-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12663-022-01730-5

Keywords

Search

Navigation